Emerging Infectious Disease Diagnostics Market Size is valued at US$ 19.23 Bn in 2022 and is predicted to reach US$ 31.76 Bn by the year 2031 at an 5.9% CAGR during the forecast period for 2023-2031.
Infectious disease diagnosis is a diagnostic procedure in which various diagnostic tools are used to detect and characterise the causative organisms of infectious diseases.
The COVID-19 pandemic certainly affected the market for infectious disease diagnostics. The COVID-19 pandemic has surged the need to develop diagnostic instruments and tests. For instance, in March 2023, QuidelOrtho Corporation received a De Novo Food and Drug Administration (FDA) Authorization for Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19. Additionally, in March 2020, BioMedomics introduced a COVID-19 point-of-care (POC) test that can identify antibodies in blood within 15 minutes.
Growth of the infectious disease diagnostics market is mainly driven by the increasing occurrence of infectious diseases such as COVID-19, human immunodeficiency virus (HIV), hepatitis, and influenza, high demand for point-of-care diagnostic tests, technological advancement in the healthcare sector, and rising government funding for diagnostic services. However, the lack of adequate reimbursements and high healthcare costs hamper the growth of the infectious disease diagnostics market.
Competitive Landscape
Some of the Key Players in the Emerging Infectious Disease Diagnostics Market :
- Abbott Laboratories
- Becton, Dickinson and Company
- bioMérieux S.A.
- Bio-Rad Laboratories, Inc.
- Co-Diagnostics, Inc.
- DANAHER CORPORATION
- DiaSorin S.p.A.
- Hoffmann-La Roche Ltd
- Hologic, Inc.
- QIAGEN N.V.
- QuidelOrtho Corporation
- T2 Biosystems, Inc.
- Tecan Trading AG
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
- Other Prominent Players
Market Segmentation:
The Emerging Infectious Disease Diagnostics Market is segmented based on application, technology, type of infection, disease type, and end users. The application segment comprises laboratory testing and point-of-care testing. By technology, the market is segregated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), immunodiagnostics, and other technologies. By type of infection, the market is categorized into bacterial, viral, fungal, and other infections. The market is classified by disease type into respiratory infections, sexually transmitted infections (STIs), gastrointestinal infections, and other infections. The end users segment has been grouped into hospitals & clinics, diagnostic laboratories, and other end users.
By Application, The Point-Of-Care Testing Segment Records Significant Growth Over The Forecast Period.
Point-of-care (POC) testing for infectious diseases enables immediate & rapid detection and decision-making. POC tests are designed to be simple, easy to use, and suitable for use in many clinical settings. It facilitates diagnosis and timely decision-making with rapid results, often within minutes or hours; this is especially important for infectious diseases, improving patient outcomes and preventing further transmission.
POC tests can help reduce the spread of disease in the region by providing timely and accurate disease detection in resource-constrained environments.
The Next-Generation Sequencing (NGS) Segment Is Expected To Drive The Emerging Infectious Disease Diagnostics Market In The Upcoming Years.
Next-generation sequencing (NGS) has transformed the diagnosis of infectious diseases by enabling high-throughput analysis of genomes. Whole Genome Sequencing (WGS) sequences an organism's entire genome, providing detailed information about genetic mutations, immune responses, and other diseases. It can identify and characterize pathogens, monitor infections, and analyze evolutionary patterns. Other emerging technologies expected to experience significant growth include technologies such as polymerase chain reaction (PCR) and isothermal nucleic acid amplification technology (INAAT).
Bacterial And Viral Infections Register The Highest Growth In The Market.
There are many methods and techniques for detecting the presence of bacteria in clinical specimens. Bacterial infections include respiratory infections such as streptococcal infections and tuberculosis and sexually transmitted infections (STIs) such as syphilis, chlamydia, and gonorrhoea.
Viruses are capable of mutating and, therefore, can cause relapse even after one strain of the virus has been eradicated or brought under control. That's why molecular testing companies focus on developing tests that can diagnose a huge range of viruses. Some common viral infections include COVID-19, hepatitis, influenza, genital herpes, tuberculosis, gastroenteritis, rubella, Zika, Ebola, and others.
Respiratory Infections Are Expected To Lead The Market.
Most molecular diagnostic companies offer tools or tests for detecting bacteria & viruses that cause respiratory diseases. In addition, the COVID-19 outbreak has led manufacturers to develop many tests using traditional & advanced methods such as RT-PCR and modern technologies like RT-LAMP and CRISPR. Many pharmaceutical companies now offer multiplex assays that simultaneously detect respiratory syncytial virus (RSV), influenza A, influenza B, and SARS-CoV-2 in a single assay test.
By End Users, The Hospitals And Clinics Witnessed Growth At A Rapid Rate.
Hospitals and clinics play a key role in the diagnosis of infectious diseases and serve as important centres for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics can rely on laboratory testing for comprehensive analysis. Some medical facilities have their own laboratories equipped with the most modern diagnostic technology, and others cooperate with external diagnostic laboratories for specialised testing. These laboratory facilities use a variety of methods, including molecular techniques such as polymerase chain reaction (PCR) and sequencing, to accurately detect, classify, and analyse infectious agents.
Regionally, North America Led The Emerging Infectious Disease Diagnostics Market In 2022.
The North American emerging infectious disease diagnostics market is estimated to have significant market revenue during the forecast period due to the presence of key players, the high prevalence of infectious diseases, technological advancements in diagnostic instruments, and growing investments in the healthcare sector.
However, the emerging infectious disease diagnostics market in the Asia Pacific is anticipated to be the fastest-growing regional market in the upcoming years. Factors such as the expanding prevalence of infectious diseases, growing government spending in the health sector, well-established healthcare infrastructure, and rising awareness about advanced diagnostic tools contribute to market expansion.
Emerging Infectious Disease Diagnostics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 19.23 Bn |
|
Revenue Forecast In 2031 |
USD 31.76 Bn |
|
Growth Rate CAGR |
CAGR of 5.9 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, Technology, Type of Infection, Disease Type, End Users |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Abbott Laboratories, Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories, Inc., Co-Diagnostics, Inc., DANAHER CORPORATION, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Hologic, Inc., QIAGEN N.V., QuidelOrtho Corporation, T2 Biosystems, Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Siemens Healthineers AG, and Others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
